137 results

   Federal Reserve chair Janet Yellen (above), speaking in New York,  re-affirmed the Fed’s commitment to keep interest rates low, even after ending its bond buying program, as long as inflation remains under target and unemployment elevated. Photograph Reuters/Larry Downing

Global equity markets advanced broadly yesterday after China reported growth that beat expectations, providing relief to investors worried abo(...)

Shire’s Vyvanse failed to ease symptoms of attention deficit hyperactivity disorder

Pharmaceuticals group Shire has halted development of its top-selling hyperactivity drug Vyvanse as a treatment for depression after it failed to trea(...)

 US stocks barely budged in thin trading after investors found little reason to add significant new positions with the Dow and the S&P 500 on a five-week winning streak. Photographer: Gino Domenico /Bloomberg

Better than forecast industrial data from China gave a boost to stocks on this side of the Atlantic while in the US the markets were becalmed as the b(...)

 Shire latched onto the rare disease drugs trend years before bigger rivals. Photographer: JB Reed/Bloomberg

London-listed Shire is buying ViroPharma for $4.2 billion its biggest deal yet to strengthen its portfolio of lucrative drugs to treat rare diseases, (...)

The percentage increase in profit excluding some items this year will be in the mid to high teens because the company sees benefits from its cost cutting, Shire said. Photograph: JB Reed/Bloomberg News.

Shire rose the most in seven years after increasing its full-year profit forecast as a reorganisation of the UK drugmaker led to lower costs. Shire so(...)

Sanofi, which manufacturers colon cancer drug Zaltrap, is suffering at the hands of generic competition.

Sanofi, France’s largest drugmaker, reported a larger-than-expected, 34 per cent, decline in first-quarter profit, crimped by generic competiti(...)

Eimear Kenny (left), ICON’s HR vice-president, and Helen Brophy, director of executive education with the UCD Michael Smurfit Graduate Business School

Leading global contract research organisation ICON has teamed up with the UCD Michael Smurfit Graduate Business School to establish the ICON Bu(...)

  • « First
  • Prev
  • 11
  • 12
  • 13
  • 14